GT
TXG icon

Glenmede Trust’s 10x Genomics TXG Stock Holding History

Glenmede Trust’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$287K Buy
+7,490
New +$196K ﹤0.01% 1201
2022
Q3 		– Sell
-6,707
Closed -$303K – 1333
2022
Q2 		$303K Buy
6,707
+1,657
+33% +$86K ﹤0.01% 1001
2022
Q1 		$384K Buy
5,050
+48
+1% +$4.2K ﹤0.01% 973
2021
Q4 		$745K Sell
5,002
-3
-0.1% -$460 ﹤0.01% 820
2021
Q3 		$728K Sell
5,005
-148
-3% -$25.4K ﹤0.01% 790
2021
Q2 		$1.01M Buy
+5,153
New +$933K 0.01% 703

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Glenmede Trust's TXG Position: Q2 2026 in Review

Glenmede Trust opened a new position in 10x Genomics (TXG) in Q2 2026: 7,490 shares worth $287K. The stake represents ﹤0.01% of the portfolio and ranks #1201 among its holdings. This is a return to the name: Glenmede Trust previously reported a position in TXG as recently as Q2 2022.

Glenmede Trust first reported a position in TXG in Q2 2021 and has held it in 6 quarters since. The position peaked at $1.01M in Q2 2021. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Glenmede Trust held 7,490 shares of 10x Genomics worth $287K as of Q2 2026.
  • 10x Genomics was a new Glenmede Trust position in Q2 2026.
  • 10x Genomics made up ﹤0.01% of Glenmede Trust's portfolio in Q2 2026, its #1201 holding.
  • Glenmede Trust first reported a position in 10x Genomics in Q2 2021 and has held it in 6 quarters since.
  • Glenmede Trust's 10x Genomics position peaked at $1.01M in Q2 2021.
  • 392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.